Find Reports

Select Report Type

Learn More about Reports

Reimbursement Review

Displaying 1401 - 1422 of 1422

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 576 - 600 of 600

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 1601 - 1625 of 2132

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Darzalex for Multiple Myeloma – Details	pcodr_daratumumab_darzalex_mm_fn_rec.pdf pcodr_daratumumab_darzalex_mm_fn_cgr.pdf pcodr_daratumumab_darzalex_mm_fn_egr.pdf pcodr_daratumumab_darzalex_mm_in_rec.pdf pcodr_daratumumab_darzalex_mm_pagfdk.pdf pcodr_daratumumab_darzalex_mm_fdk_janssen.pdf pcodr_daratumumab_darzalex_mm_fdk_mc.pdf pcodr_daratumumab_darzalex_mm_fdk_clinician.pdf pcodr_daratumumab_darzalex_mm_coi_mc.pdf pcodr_daratumumab_darzalex_mm_coi_clinician.pdf	Dec 16, 2016	Reimbursement Review		Complete	PC0079-000
Eliglustat	cdr_SR0511_Cerdelga.pdf SR0511_complete_Cerdelga_Jul_28_17_e.pdf SR0511_Cerdelga_CL_Report_e.pdf SR0511_Cerdelga_PE_Report_e.pdf SR0511_Cerdelga_PI_Submissions.pdf	Dec 15, 2016	Reimbursement Review		Complete	SR0511-000
Glatiramer acetate	cdr_SE0510_Glatect.pdf SE0510_complete_Glatect-Jul-27-e.pdf SE0510_Glatect _PI_Submissions.pdf SE0510_Glatect_SENB_Complex_Drug_Submission_Report.pdf	Dec 15, 2016	Reimbursement Review		Complete	SE0510-000
Single Drug Technology Assessment Processes Across Health Technology Assessment Organizations		Dec 9, 2016	Health Technology Review	Environmental Scan	Completed	ES0293-000
Ibrance for Advanced Breast Cancer Resubmission – Details	pcodr_profund_10093_palbociclib_ibrance_abc_resub.pdf pcodr_palbociclib_ibrance_resub_abc_fn_rec.pdf pcodr_palbociclib_ibrance_resub_abc_fn_cgr.pdf pcodr_palbociclib_ibrance_resub_abc_fn_egr.pdf pcodr_palbociclib_ibrance_resub_abc_in_rec.pdf pcodr_palbociclib_ibrance_resub_abc_pagfdk.pdf pcodr_palbociclib_ibrance_resub_abc_fdk_pfizer.pdf pcodr_palbociclib_ibrance_resub_abc_ptfdk_rethink.pdf pcodr_palbociclib_ibrance_resub_abc_ptfdk_cbcn.pdf pcodr_palbociclib_ibrance_resub_abc_coi_cbcn-rethink.pdf pcodr_palbociclib_ibrance_resub_abc_coi_clinician.pdf	Dec 6, 2016	Reimbursement Review		Complete	PC0093-000
Onivyde for Metastatic Pancreatic Cancer (Closed)		Dec 2, 2016	Reimbursement Review		Cancelled	PC0096-000
Obeticholic Acid	cdr_SR0509_TBC.pdf SR0509_complete_Ocaliva_Jul_27_17_e.pdf SR0509_Ocaliva_CL_Report_e.pdf SR0509_Ocaliva_PE_Report_e.pdf SR0509 Ocaliva_PI_Submissions.pdf	Nov 24, 2016	Reimbursement Review		Complete	SR0509-000
Keytruda for Non-Small Cell Lung Cancer (Second Line or Beyond) – Details	pcodr_provfund_pembrolizumab_keytruda_nsclc_2lnbeyond.pdf pcodr_pembrolizumab_keytruda_nsclc_fn_rec.pdf pcodr_pembrolizumab_keytruda_nsclc_fn_cgr.pdf pcodr_pembrolizumab_keytruda_nsclc_fn_egr.pdf pcodr_pembrolizumab_keytruda_nsclc_in_rec.pdf pcodr_pembrolizumab_keytruda_nsclc_pagfdk.pdf pcodr_pembrolizumab_keytruda_nsclc_fdk_merck.pdf pcodr_pembrolizumab_keytruda_nsclc_ptfdk.pdf pcodr_pembrolizumab_keytruda_nsclc_coi_lcc.pdf pcodr_pembrolizumab_keytruda_nsclc_fdk_clinician.pdf pcodr_pembrolizumab_keytruda_nsclc_coi_clinician.pdf	Nov 18, 2016	Reimbursement Review		Complete	PC0077-000
Imbruvica for Chronic Lymphocytic Leukemia (previously untreated) – Details	pcodr-provfund_ibrutinib_imbruvica-cll-sll-preun.pdf pcodr_ibrutinib_imbruvica_cll-sll_fn_rec.pdf pcodr_ibrutinib_imbruvica_cll-sll_fn_cgr.pdf pcodr_ibrutinib_imbruvica_cll-sll_fn_egr.pdf pcodr_ibrutinib_imbruvica_cll-sll_in_rec.pdf pcodr_ibrutinib_imbruvica_cll-sll_pagfdk.pdf pcodr_ibrutinib_imbruvica_cll-sll_fdk_janssen.pdf pcodr_ibrutinib_imbruvica_cll-sll_ptfdk_cllpag.pdf pcodr_ibrutinib_imbruvica_cll-sll_coi_cllpag.pdf pcodr_ibrutinib_imbruvica_cll-sll_ptfdk_lc.pdf pcodr_ibrutinib_imbruvica_cll-sll_coi_lc.pdf pcodr_ibrutinib_imbruvica_cll-sll_coi_clinician.pdf	Nov 18, 2016	Reimbursement Review		Complete	PC0085-000
Imbruvica for Waldenström’s Macroglobulinemia - Details	pcodr-provfund_ibrutinib_imbruvica-wm.pdf pcodr_ibrutinib_imbruvica_wm_fn_rec.pdf pcodr_ibrutinib_imbruvica_wm_fn_cgr.pdf pcodr_ibrutinib_imbruvica_wm_fn_egr.pdf pcodr_ibrutinib_imbruvica_wm_in_rec.pdf pcodr_ibrutinib_imbruvica_wm_pagfdk.pdf pcodr_ibrutinib_imbruvica_wm_fdk_janssen.pdf pcodr_ibrutinib_imbruvica_wm_ptfdk_cord.pdf pcodr_ibrutinib_imbruvica_wm_ptfdk_lc.pdf pcodr_ibrutinib_imbruvica_wm_coi_lc_cord.pdf	Nov 18, 2016	Reimbursement Review		Complete	PC0082-000
Kyprolis (with lenalidomide) for Multiple Myeloma – Details	pcodr_profund_10067carfilzomib_kyprolis_lenalidomide_mm.pdf pcodr_carfilzomib_kyprolis_mm_fn_rec.pdf pcodr_carfilzomib_kyprolis_mm_fn_cgr.pdf pcodr_carfilzomib_kyprolis_mm_fn_egr.pdf pcodr_carfilzomib_kyprolis_mm_in_rec.pdf pcodr_carfilzomib_kyprolis_mm_pagfdk.pdf pcodr_carfilzomib_kyprolis_mm_fdk_amgen.pdf pcodr_carfilzomib_kyprolis_mm_coi_mc.pdf	Nov 11, 2016	Reimbursement Review		Complete	PC0067-000
emtricitabine/rilpivirine/ tenofovir alafenamide	cdr_SR0507_TBC.pdf SR0507_complete_Odefsey- May-25-17_e.pdf SR0507_Odefsey_Combined_Report.pdf SR0507_Odefsey_PI_Submissions.pdf	Oct 27, 2016	Reimbursement Review		Complete	SR0507-000
Daclizumab beta	cdr_SR0508_Zinbryta.pdf SR0508_compelte_Zinbryta_Jun-22-17_e.pdf SR0508_Zinbryta_CL_Report.pdf SR0508_Zinbryta_PE_Report.pdf SR0508_Zinbryta_PI_Submissions.pdf	Oct 18, 2016	Reimbursement Review		Complete	SR0508-000
Lynparza for Ovarian Cancer (2nd line) – Details	pcodr_provfund_olaparib_lynparza_oc.pdf pcodr_olaparib_lynparza_oc_fn_rec.pdf pcodr_olaparib_lynparza_oc_fn_cgr.pdf pcodr_olaparib_lynparza_oc_fn_egr.pdf pcodr_olaparib_lynparza_oc_in_rec.pdf pcodr_olaparib_lynparza_oc_pagfdk.pdf pcodr_olaparib_lynparza_oc_fdk_azc.pdf pcodr_olaparib_lynparza_oc_ptfdk.pdf pcodr_olaparib_lynparza_oc_coi_occ.pdf pcodr_olaparib_lynparza_oc_fdk_clinician.pdf pcodr_olaparib_lynparza_oc_coi_clinician.pdf	Oct 17, 2016	Reimbursement Review		Complete	PC0081-000
Zydelig for Follicular Lymphoma – Details	pcodr-provfund_idelalisib-zydelig-fl.pdf pcodr_idelalisib_zydelig_fl_fn_rec.pdf pcodr_idelalisib_zydelig_fl_fn_cgr.pdf pcodr_idelalisib_zydelig_fl_fn_egr.pdf pcodr_idelalisib_zydelig_fl_in_rec.pdf pcodr_idelalisib_zydelig_fl_pagfdk.pdf pcodr_idelalisib_zydelig_fl_fdk_gilead.pdf pcodr_idelalisib_zydelig_fl_ptfdk_lc.pdf pcodr_idelalisib_zydelig_fl_coi_lc.pdf	Oct 17, 2016	Reimbursement Review		Complete	PC0075-000
Ivabradine	cdr_SR0506_Lancora.pdf SR0506_complete_Lancora-Jun15-17_e.pdf SR0506_ Lancora_CL_Report.pdf SR0506_ Lancora_PE_Report.pdf SR0506_Lancora_PI_Submissions.pdf	Oct 11, 2016	Reimbursement Review		Complete	SR0506-000
Lenvima for Differentiated Thyroid Cancer – Details	pcodr-provfund_lenvatinib-lenvima-dtc.pdf pcodr_lenvatinib_lenvima_dtc_fn_rec.pdf pcodr_lenvatinib_lenvima_dtc_fn_cgr.pdf pcodr_lenvatinib_lenvima_dtc_fn_egr.pdf pcodr_lenvatinib_lenvima_dtc_in_rec.pdf pcodr_lenvatinib_lenvima_dtc_pagfdk.pdf pcodr_lenvatinib_lenvima_dtc_fdk_eisailtd.pdf pcodr_lenvatinib_lenvima_dtc_coi_tcc.pdf pcodr_lenvatinib_lenvima_dtc_coi_clinicians.pdf	Oct 5, 2016	Reimbursement Review		Complete	PC0080-000
Liraglutide	cdr_SR0505_Victoza_Resubmission.pdf	Sep 21, 2016	Reimbursement Review		Withdrawn	SR0505-000
Opdivo for Metastatic Renal Cell Carcinoma – Details	pcodr-provfund_nivolumab-opdivo-mrcc.pdf pcodr_nivolumab_opdivo_mrcc_fn_rec.pdf pcodr_nivolumab_opdivo_mrcc_fn_cgr.pdf pcodr_nivolumab_opdivo_mrcc_fn_egr.pdf pcodr_nivolumab_opdivo_mrcc_in_rec.pdf pcodr_nivolumab_opdivo_mrcc_pagfdk.pdf pcodr_nivolumab_opdivo_mrcc_fdk_bms.pdf pcodr_nivolumab_opdivo_mrcc_ptfdk_kcc.pdf pcodr_nivolumab_opdivo_mrcc_coi_kcc.pdf	Sep 19, 2016	Reimbursement Review		Complete	PC0074-000
Sarilumab	cdr_SR0503_TBC.pdf SR0503_Kevzara_CL_Report.pdf SR0503_Kevzara_PE_Report.pdf SR0503_Kevzara_PI_Submissions.pdf SR0503_complete_Kevzara-Apr-20-17.pdf	Sep 13, 2016	Reimbursement Review		Complete	SR0503-000
Propiverine hydrochloride	cdr_SR0504_Mictoryl.pdf SR0504_Mictoryl_CL Report.pdf SR0504_Mictoryl_PE_Report.pdf SR0504_Mictoryl_PI_Submissions.pdf SR0504_complete_Mictoryl_Apr-21-17-e.pdf	Sep 9, 2016	Reimbursement Review		Complete	SR0504-000
Yondelis for Liposarcoma or Leiomyoscarcoma – Details	pcodr_provfund_trabectedin_yondelis_lipo-leio.pdf pcodr_trabectedin_yondelis_lile_scarcoma_fn_rec.pdf pcodr_trabectedin_yondelis_lile_scarcoma_fn_cgr.pdf pcodr_trabectedin_yondelis_lile_scarcoma_fn_egr.pdf pcodr_trabectedin_yondelis_lile_scarcoma_in_rec.pdf pcodr_trabectedin_yondelis_lile_scarcoma_pagfdk.pdf pcodr_trabectedin_yondelis_lile_scarcoma_fdk_janssen.pdf pcodr_trabectedin_yondelis_lile_scarcoma_coi_scfc.pdf	Aug 22, 2016	Reimbursement Review		Complete	PC0071-000
Avastin for Platinum-Resistant Ovarian Cancer – Details	pcodr-provfund_bevacizumab_avastin_proc.pdf pcodr_bevacizumab_avastin_proc_fn_rec.pdf pcodr_bevacizumab_avastin_proc_fn_egr.pdf pcodr_bevacizumab_avastin_proc_fn_cgr.pdf pcodr_bevacizumab_avastin_proc-in_rec.pdf pcodr_bevacizumab_avastin_proc_pagfdk.pdf pcodr_bevacizumab_avastin_proc_fdk_roche.pdf pcodr_bevacizumab_avastin_proc_ptfdk_occ.pdf pcodr_bevacizumab_avastin_proc_coi_occ.pdf	Aug 15, 2016	Reimbursement Review		Complete	PC0066-000
Opdivo for Non-Small Cell Lung Cancer – Details	pcodr_provfund_nivolumab_opdivo_nsclc.pdf nivolumab_opdivo_nsclc_fn_rec.pdf nivolumab_opdivo_nsclc_fn_cgr.pdf nivolumab_opdivo_nsclc_fn_egr.pdf nivolumab_opdivo_nsclc_in_rec.pdf nivolumab_opdivo_nsclc_pagfdk.pdf nivolumab_opdivo_nsclc_fdk_bms.pdf nivolumab_opdivo_nsclc_coi_lcc.pdf	Aug 15, 2016	Reimbursement Review		Complete	PC0069-000
ustekinumab	cdr_SR0501_Stelara.pdf SR0501_complete_Stelara_Mar-23-17.pdf SR0501_Stelara_CL_Report.pdf SR0501_Stelara_PE_Report.pdf SR0501_Stelara_PI_Submissions.pdf	Aug 12, 2016	Reimbursement Review		Complete	SR0501-000